Key result
IFN-alpha increases plaque lipopolysaccharide-triggered TNF-alpha secretion by ~150%.
Why the study?
The contribution of interferon-alpha to inflammation and tissue injury in the atherosclerotic plaque microenvironment was unclear.
Absolute Event Rate: 559% vs 225.1%
p-value: p=<0.001
IFN-alpha acts as an inflammatory amplifier in atherosclerotic plaques, sensitizing antigen-presenting cells to TLR4 ligands and increasing the production of destabilizing cytokines.
IFN-alpha may promote plaque inflammation and injury; leaves open whether targeting it modifies atherosclerosis.
BACKGROUND: Interferon (IFN)-alpha is a pluripotent inflammatory cytokine typically induced by viral infections. In rupture-prone atherosclerotic plaques, plasmacytoid dendritic cells produce IFN-alpha. In the present study we explored the contribution of IFN-alpha to inflammation and tissue injury in the plaque microenvironment. METHODS AND RESULTS: In 53% of carotid plaques (n=30), CD123+ plasmacytoid dendritic cells clustered together with CD11c+ myeloid dendritic cells, a distinct dendritic cell subset specialized in sensing danger signals from bacteria and tissue breakdown. Tissue concentrations of IFN-alpha and tumor necrosis factor (TNF)-alpha transcripts were tightly correlated (r=0.76, P<0.001), suggesting a regulatory role of IFN-alpha in TNF-alpha production. Plaque tissue stimulation with CpG ODN, a Toll-like receptor (TLR) 9 ligand, increased IFN-alpha production (57.8+/-23.7 versus 25.9+/-8.6 pg/mL; P<0.001), whereas the TLR4 ligand lipopolysaccharide induced TNF-alpha secretion (225.1+/-3.0 versus 0.7+/-0.2 pg/mL; P<0.001). Treating plaque tissue with IFN-alpha markedly enhanced lipopolysaccharide-triggered TNF-alpha secretion (559.0+/-25.9 versus 225.1+/-3.0 pg/mL; P<0.001). IFN-alpha pretreatment also amplified the effects of lipopolysaccharide on interleukin-12, interleukin-23, and matrix metalloproteinase-9, suggesting that the antiviral cytokine sensitized myeloid dendritic cells and macrophages toward TLR4 ligands. Mechanistic studies demonstrated that IFN-alpha modulated the myeloid dendritic cell response pattern by upregulating TLR4 expression (P<0.001) involving both the STAT (signal transducer and activator of transcription) and the PI(3)K pathway. CONCLUSIONS: In the atherosclerotic plaque, IFN-alpha functions as an inflammatory amplifier. It sensitizes antigen-presenting cells toward pathogen-derived TLR4 ligands by upregulating TLR4 expression and intensifies TNF-alpha, interleukin-12, and matrix metalloproteinase-9 production, all implicated in plaque destabilization. Thus, IFN-alpha-inducing pathogens, even when colonizing distant tissue sites, threaten the stability of inflamed atherosclerotic plaque.
No takes yet. Share an insight, caveat, or question.
Niessner et al. (2007) studied Atherosclerotic plaque (n=30). IFN-alpha pretreatment vs. Lipopolysaccharide alone was evaluated on Lipopolysaccharide-triggered TNF-alpha secretion (pg/mL) (p=<0.001). Treating atherosclerotic plaque tissue with IFN-alpha markedly enhanced lipopolysaccharide-triggered TNF-alpha secretion (559.0 vs 225.1 pg/mL; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: